bacitracin (polysporin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.   NCATS

Chemistry

  • SMILES: CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC
  • InChIKey: CLKOFPXJLQSYAH-ABRJDSQDSA-N
  • Mol. Mass: 1422.72
  • ALogP: Missing data
  • ChEMBL Molecules:
    bacitracin  
    bacitracin zinc  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral, Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0417 - $25.1088
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( urea, bacitracin (polysporin), neomycin, polymyxin b sulfate (poly-rx) - other names: bacitracin-neomycin-polymyxin w/ hydrocortisone acetate, neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone )
|
( lidocaine (xylocaine), bacitracin (polysporin), neomycin, polymyxin b sulfate (poly-rx) )
|
( bacitracin (polysporin), neomycin, polymyxin b sulfate (poly-rx) - other name: neomycin and polymyxin b sulfates and bacitracin zinc )
|
( bacitracin (polysporin), polymyxin b sulfate (poly-rx) )

Alternative names

albac 50 | baciferm 50 | baciguent | baciim | bacillichin | bacilliquin | baci-rx | bacitracin | bacitracin f, 1-(n-((2-(1-amino-2-methylbutyl)-4,5-dihydro-4-thiazolyl)carbonyl)-l-leucine)- | bacitracin zinc | e700

Organizations (47)

Research & Development (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (4)


 

Eye Infections, Bacterial (approved 1968)

Infections

Pneumonia

Skin Diseases (approved 1957)

Experimental Indications - Clinical Trial Phases 1-4 (24)


 

Allergy and Immunology (Phase 4)

Arrhythmias, Cardiac (Phase 3)

Arteriovenous Fistula (Phase 4)

Breast Diseases (Phase 1)

Burns (Phase 4)

Dermatitis, Allergic Contact (Phase 2)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Foot (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Edema (Phase 2/Phase 3)

Eyelid Diseases (Phase 4)

General Surgery (Phase 4)

Infections ()

Kidney Failure, Chronic (Phase 4)

Mammaplasty (Phase 1)

Melanoma (Phase 2)

Paranasal Sinus Diseases (Phase 2)

Sinusitis (Phase 4)

Skin Neoplasms (Phase 4)

Surgical Wound (Phase 4)

Surgical Wound Infection (Phase 4)

Urinary Tract Infections (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 29
  • # of Trial Organizations: 33

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue